Thomas Steyer’s Cardiff Oncology CRDF Stock Holding History

Thomas Steyer’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200,000	Closed	-$2.84M	–	142
2020 Q3	$2.84M	Buy	+200,000	New	+$1.32M	0.02%	117

Other funds holding CRDF

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Thomas Steyer's CRDF Position: Q4 2020 in Review

Thomas Steyer sold out of Cardiff Oncology (CRDF) in Q4 2020, closing a stake of 200,000 shares — an estimated $2.84M sold.

Thomas Steyer first reported a position in CRDF in Q3 2020 and held it in 1 quarter. The position peaked at $2.84M in Q3 2020. 82 funds tracked by Wall St. Rank hold CRDF as of Q4 2020.

Thomas Steyer reported no remaining Cardiff Oncology position as of Q4 2020 after selling out during the quarter.
Thomas Steyer sold 200,000 Cardiff Oncology shares in Q4 2020, an estimated $2.84M.
Thomas Steyer first reported a position in Cardiff Oncology in Q3 2020 and held it in 1 quarter.
Thomas Steyer's Cardiff Oncology position peaked at $2.84M in Q3 2020.
82 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.